Astria Therapeutics Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2015 - 2019
Period Ending	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2015 - 2019
Net Income	-94.26	-72.89	-51.83	-194.91	-37.3	Upgrade
Asset Writedown & Restructuring Costs	-	-	-	164.61	-	Upgrade
Loss (Gain) From Sale of Investments	-5.61	-0.09	-	-	-	Upgrade
Stock-Based Compensation	13.04	6.31	4.55	3.36	1.39	Upgrade
Other Operating Activities	1.07	0.63	1.1	0.66	0.06	Upgrade
Change in Accounts Payable	2.81	0.73	-0.77	-1.97	0.35	Upgrade
Change in Other Net Operating Assets	1.74	-3.14	3.41	-1.91	3.02	Upgrade
Operating Cash Flow	-81.21	-68.45	-43.53	-30.15	-32.49	Upgrade
Capital Expenditures	-0.33	-0.03	-0.09	-0.02	-0.03	Upgrade
Cash Acquisitions	-	-	-	6.47	-	Upgrade
Investment in Securities	-191.54	135.08	-167.04	-19	6.33	Upgrade
Investing Cash Flow	-191.86	135.05	-167.13	-12.56	6.3	Upgrade
Issuance of Common Stock	157.2	88.4	144.72	104.28	40.86	Upgrade
Financing Cash Flow	157.2	88.4	144.72	104.28	40.86	Upgrade
Net Cash Flow	-115.87	155.01	-65.94	61.58	14.68	Upgrade
Free Cash Flow	-81.54	-68.47	-43.62	-30.17	-32.52	Upgrade
Free Cash Flow Per Share	-1.45	-2.27	-2.98	-3.38	-10.63	Upgrade
Levered Free Cash Flow	-52.58	-36.52	-25.02	-16.71	-18.79	Upgrade
Unlevered Free Cash Flow	-52.58	-36.52	-25.02	-16.71	-18.79	Upgrade
Change in Net Working Capital	-4.43	0.42	-3.95	1.08	-3.25	Upgrade

Updated Mar 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q